INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Champignon Brands Inc. Investors

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Champignon Brands Inc. ("Champignon" or the "Company") (OTC: SHRMF ) securities between March 27, 2020 and February 17, 2021 , inclusive (the "Class Period"). Champignon investors have until June 9, 2021 to file a lead plaintiff motion.

Investors suffering losses on their Champignon investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com .

On June 22, 2020, Champignon announced that the Company had "been selected for continuous disclosure review by the British Columbia Securities Commission (the "Commission") and "in connection with the review, the Commission had issued a cease trade order suspending in the securities of the Company pending the filing of business acquisition reports."

On this news, the Company's stock price fell 24% to close at $0.500 per share on June 22, 2020, thereby damaging investors.

On September 15, 2020, the Company issued a press release stating, amongst other things, "the Commission issued a replacement cease trade order . . . , pending the filing of a revised material change report . . . in connection with the acquisition by the Company of AltMed." Champignon further stated that "the acquisition of AltMed should be treated as a reverse-takeover."

On this news, Champignon's stock price fell 5% to close at $0.271 per share on September 16, 2020, thereby damaging investors.

On February 17, 2021, Champignon announced that it would restate its financial statements for the three and six month periods ended March 31, 2020. Specifically, "the Company previously recognized intangible assets in connection with" certain acquisitions, and "management determined that . . . the assets do not meet the definition of intangible assets for the purposes of international financial reporting standards and as result will be recorded as transaction costs in the Company's statement of loss and comprehensive loss." Champignon also stated that "a shareholder and contracted consultant (the ‘Consultant') of the Company was a related party with respect to" those acquisitions.

On this news, Champignon's stock price fell 10% to close at $0.687 per share on February 17, 2021, thereby damaging investors further.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Champignon had undisclosed material weaknesses and insufficient financial controls; (2) Champignon's previously issued financial statements were false and unreliable; (3) Champignon's earlier reported financial statements would need to be restated; (4) Champignon's acquisitions involved an undisclosed related party; (5) as a result of the foregoing and subsequent reporting delays and issues, the British Columbia Securities Commission would suspend Champignon's stock from trading; (6) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you purchased Champignon securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com , or visit our website at www.howardsmithlaw.com .

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
"2023 year-end review" text overlaid on image of psychedelic mushrooms.

Psychedelics Market 2023 Year-End Review

The psychedelics industry is maturing after the investment boom of 2020 and 2021, and patient long-term investors looking for opportunities to diversify their portfolios have options when it comes to exposure. As clinical trials and research continue to demonstrate the potential benefits of... Keep Reading...
Glowing pyschedelic mushrooms.

How to Invest in Psychedelics

Market participants are wondering how to invest in psychedelics as the opportunity attached to these drugs grows.Promising research associated with psychedelic medicine shows the potential for these products to treat mental health issues and even addiction to opioids. “(Psychedelic)-assisted... Keep Reading...
A colorful brain illustrating brain on pyschedelics.

Psychedelics Stocks to Watch

The small-cap market has been invaded by a flurry of psychedelics stocks to watch thanks to new company launches. Investors now have a variety of options for taking a run in the shroom stocks space.In an effort to expand the capabilities of the medical field, companies are starting to... Keep Reading...
pink mushrooms under ultraviolet light

What Does the FDA Think About Psychedelics?

The development of the growing psychedelics industry depends on myriad factors, but one of the most critical is its relationship with a principal medical authority.The US Food and Drug Administration (FDA) is the leading body for drug approvals in the US. Its job is to review clinical data from... Keep Reading...

Interactive Chart

Latest Press Releases

Related News